Results 141 to 150 of about 2,336,278 (343)
We discuss the status of the Standard Model (SM): the principles; the Lagrangian; the problems; open questions and the ways beyond. Then we consider possible physics beyond the SM: New symmetries (Gauge, SUSY); New particles (gauge, axion, superpartners); New dimensions (extra, large, compact, etc) or a New Paradigm (strings, branes, gravity).
openaire +3 more sources
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim +11 more
wiley +1 more source
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima +6 more
wiley +1 more source
Impact of vacuum stability constraints on the phenomenology of supersymmetric models
We present a fast and efficient method for studying vacuum stability constraints in multi-scalar theories beyond the Standard Model. This method is designed for a reliable use in large scale parameter scans.
Wolfgang G. Hollik +2 more
doaj +1 more source
Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation
Cyclin D1 overexpression altered the cell adhesion pathway, while cyclin D2 upregulation had less impact on pathway enrichment analysis. Multiple myeloma (MM) patients with cyclin D1 overexpression showed reduced CD56 expression and increased circulating tumor cells (CTC) levels, suggesting that cyclin D1 may contribute to MM cell dissemination ...
Ignacio J. Cardona‐Benavides +13 more
wiley +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
CP violation beyond the standard model and tau pair production in e+e− collisions [PDF]
W. Bernreuther +2 more
openalex +1 more source
Physics Beyond the Standard Model
54 pages, 7 figures, to appear in the Proceedings of the 1999 Lake Louise Winter Institute, Lake Louise, Canada, February ...
openaire +3 more sources
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
Decrypting cancer's spatial code: from single cells to tissue niches
Spatial transcriptomics maps gene activity across tissues, offering powerful insights into how cancer cells are organised, switch states and interact with their surroundings. This review outlines emerging computational, artificial intelligence (AI) and geospatial approaches to define cell states, uncover tumour niches and integrate spatial data with ...
Cenk Celik +4 more
wiley +1 more source

